Also trades as: LOBE.CN (CNQ) · $vol 0M
LOBEF OTC
Lobe Sciences Ltd.
1W: -20.3%
1M: -35.6%
3M: -45.2%
YTD: +10.4%
1Y: +9.5%
3Y: +106.0%
$0.04
+0.00 (+3.38%)
Weekly Expected Move ±15.0%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$11.3M
52W Range0.0021-0.10855
Volume220
Avg Volume63,725
Beta0.28
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOFrederick Dominick Sancilio
SectorHealthcare
IndustryBiotechnology
IPO Date2023-08-24
Websitelobesciences.com
1771 Robson Street
Vancouver, BC V6G 3B7
CA
Vancouver, BC V6G 3B7
CA
949-505-5623
About Lobe Sciences Ltd.
Lobe Sciences Ltd. is a life sciences company focused on researching and advancing psychedelic-based medicines. Their primary therapeutic development involves psilocybin-derived treatments combined with N-acetylcysteine, specifically for addressing mild traumatic brain injuries (mTBI) and post-traumatic stress disorder (PTSD). Additionally, they engineer specialized devices aimed at enhancing the efficiency of drug administration. This organization, headquartered in Vancouver, Canada, underwent a name change from Greenstar Biosciences Corp. to Lobe Sciences Ltd. in November 2020.
Latest News
Lobe Sciences to raise C$2.1M in private placement
Lobe Sciences launches non-brokered private placement of 14.62M shares at $0.065
Lobe Sciences names Mirza Rahimani as CFO; succeeds Yong Yao
Lobe Sciences Reports First Quarter 2026 Results and Highlights
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
Recent Insider Trades
No insider trades found